Rogco LP Sells 670 Shares of Merck & Co., Inc. (NYSE:MRK)

Rogco LP trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 7.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,068 shares of the company’s stock after selling 670 shares during the quarter. Rogco LP’s holdings in Merck & Co., Inc. were worth $916,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Itau Unibanco Holding S.A. bought a new position in Merck & Co., Inc. in the 2nd quarter valued at $39,000. Abich Financial Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 121.8% in the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares in the last quarter. Quarry LP bought a new position in shares of Merck & Co., Inc. in the second quarter valued at about $42,000. Strategic Financial Concepts LLC lifted its position in Merck & Co., Inc. by 1,475.6% during the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after buying an additional 32,832 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC grew its holdings in Merck & Co., Inc. by 47.5% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock worth $43,000 after acquiring an additional 122 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of research analyst reports. Wolfe Research raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, July 31st. Truist Financial reduced their price objective on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Barclays dropped their target price on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, October 7th. Wells Fargo & Company lowered their price objective on Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 31st. Finally, Evercore ISI upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $131.62.

Merck & Co., Inc. Trading Down 0.8 %

NYSE:MRK traded down $0.89 during trading hours on Thursday, hitting $105.49. The stock had a trading volume of 2,333,648 shares, compared to its average volume of 8,762,497. Merck & Co., Inc. has a one year low of $99.80 and a one year high of $134.63. The company has a market cap of $267.19 billion, a price-to-earnings ratio of 117.92, a P/E/G ratio of 1.55 and a beta of 0.39. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. The business’s 50 day moving average is $113.86 and its 200-day moving average is $121.93.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.12. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The business had revenue of $16.10 billion during the quarter, compared to analysts’ expectations of $15.87 billion. During the same period in the prior year, the business earned ($2.06) EPS. Merck & Co., Inc.’s revenue for the quarter was up 7.1% compared to the same quarter last year. Sell-side analysts anticipate that Merck & Co., Inc. will post 7.88 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.